Michael R. Grunwald, MD
While tremendous strides have been made in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), challenges remain in both paradigms, including optimal sequencing and managing toxicity profiles, explained Michael R. Grunwald, MD.
on Hematologic Malignancies, Grunwald, a physician at Levine Cancer Institute, discussed new and emerging agents in AML and ALL, as well as sequencing and toxicity challenges with these treatments.
OncLive: Please provide an overview of your presentation.
: I presented on new therapies in acute leukemia, specifically AML and ALL. For many decades, we didn't have new therapies, especially for AML. Over the past few years, especially this past year, we've gotten some exciting new drug approvals in both AML and ALL.
... to read the full story